References
- Dune BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842–854.
- Greipp PR. Advances in the diagnosis and management of myeloma. Sem Hematol 1992;29:24–45.
- Gassman W, Pralle H, Haferlach T, Pandurevic S, Graubner M, Schmitz N, et al. Staging systems for multiple myeloma: A comparison. Br J Haematol 1985;59:703–711.
- Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
- Greipp PR, Katzman JA, O'Fallon WM, Kyle RA. Value of 132-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988;72: 219.
- Bataille R, Dune GM, Grenier J, Sany J. Prognostic factors and staging in multiple myeloma. A reappraisal. J Chin Oncol 1986;4:80–87.
- Jacobson JL, Hussein MA, Barlogie B, Dune BGM, Crowley JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003;122:441–450.
- Greipp PR, San Miguel J, Dune BGM, Crowley J, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Chin Oncol 2005;23:3412–3420.
- Weber D, Wang M, Delasalle K, Alexanian R. Confirmation of prognostic value of model using B2 microglobulin (B2M) and albumin for multiple myeloma (MM) proposed by the International Myeloma Working Group (INIWG) with similar results using B2M alone. Blood 2003;102(11), abstract.
- Bataille R, Dune BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging. Br J Haematol 1983;55: 439–447.
- Bjerrum OW, Plesner T. Beta-2 microglobulin: A valuable parameter of stage, prognosis and response to treatment in myelomatosis. Scand J Haematol 1985;35:22–25.
- Cuzick J, De Stavola BL, Cooper EH, Chapman C, Mac Lennan IC. Long-term prognostic value of serum 132 microglobulin in myelomatosis. Br J Haematol 1990;75: 506–510.
- Bataille R, Grenier J, Sany J. Beta-2-microglobulin in myeloma: Optimal use for staging, prognosis and treat-ment—a prospective study of 160 patients. Blood 1984;63: 468–476.
- Bernier GM, Cohen RJ, Conrad ME. Microglobulinemia in renal failure. Nature 1968;218:598–599.
- Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Chin Invest 198984:2008-2011.
- Lichtenstein A, Tu Y, Fady C, et al. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995;162: 248–255.